June 24, 2014
The results from a PIII clinical study of Takeda Pharmaceutical’s once-weekly formulation of trelagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, conducted in Japan in patients with type 2 diabetes, were presented at the Scientific Session of the American Diabetes Association (ADA)...read more